Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

NCT07148947

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Washington
Enrollment	27 participants

Key Eligibility Criteria

Inclusion (15)

- Age e 18 years
- History of myeloproliferative neoplasms (MPN) as defined by the 2016 and 2022 World Health Organization criteria, with now pathologically confirmed e 5% blasts in the bone marrow or peripheral blood. Prior MPNs could include polycythemia vera, essential thrombocythemia, primary myelofibrosis, secondary myelofibrosis, MPN-unclassifiable, and myelodysplastic syndrome (MDS)/MPN overlap syndromes
- Outside diagnostic material is acceptable. Internal review at the study institution of outside peripheral blood and/or bone marrow slides is recommended. Flow cytometric analysis of peripheral blood and/or bone marrow should be performed according to institutional practice guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 OR Karnofsky e 60%
- Serum creatinine clearance e 50 ml/min calculated by the Cockcroft-Gault Equation (assessed within 14 days of study day 1)

... and 10 more (see full listing online)

Exclusion (7)

- Previous treatment with chemotherapy (e.g. hypomethylating agents or cytarabine-based regimens) for MPN (does not include the first cycle of treatment with an allowable HMA initiated within 30 days prior to start of pacritinib). Prior temporary measures to control blood counts is allowed. Prior treatment with hydroxyurea, interferons or JAK inhibitor therapy (including pacritinib) is allowed
- Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired \[e.g. chronic viral hepatitis, HIV\])
- Known hypersensitivity to any study drug
- Females who are pregnant or breastfeeding (Women of childbearing potential \[WOCBP\] must have a negative serum pregnancy test within 14 days prior to enrollment)
- Treatment with any other anti-MDS/leukemia investigational agent within 2 weeks of start of study drugs

... and 2 more (see full listing online)

Locations (1 total)

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States